Israeli media reports indicate the military now estimates around 70,000 Palestinian fatalities in Gaza, a figure aligning with earlier Hamas-run health ministry counts it had previously questioned.
The SAS subsidiary's new enhancement leverages vastly expanded consumer rate shopping data, offering hoteliers granular visibility across room types and distribution channels to refine pricing strategies.
Despite a premium valuation, AMD is positioning itself as a key challenger in the AI chip race, betting big on integrated data center systems to capture surging demand.
SAP discontinues its legacy IS-H healthcare software in the DACH region, impacting dozens of hospitals, while appointing David Robinson to lead its crucial North American operations. The moves signal a strategic pivot as the enterprise software giant navigates a complex market landscape.
Consumer goods giant Procter & Gamble has agreed to acquire Wonderbelly, a fast-growing brand in the 'free-from' digestive health space, signaling a deeper push into the lucrative wellness category and a bid to attract younger, label-conscious consumers.
Proposed flat payment rates for 2027 by CMS intensify margin pressures on Medicare Advantage insurers like Clover Health, raising investor concerns about cost management and growth prospects in a tightening regulatory landscape.
Bloom Energy's stock surged after American Electric Power's subsidiary locked in a massive 20-year fuel cell agreement, a move analysts say validates the company's technology for critical infrastructure like AI data centers and signals a pivotal shift in its growth narrative.
Brookfield Infrastructure Partners capped a strong 2025 with double-digit FFO growth, a record capital recycling program, and a raised distribution. Management highlighted a massive, disciplined expansion in data infrastructure to meet AI-driven demand, forecasting a return to 10%+ growth targets.
Facing uneven long-term performance, UPS announces a major strategic overhaul involving significant job reductions, facility closures, and a deliberate move away from low-margin Amazon volume. The company is betting big on healthcare logistics through acquisitions to bolster its global cold chain network.
The U.S. dollar climbed to a one-week high, buoyed by unexpectedly strong manufacturing activity and hawkish-leaning Federal Reserve commentary. The rally pressured major currency pairs and sent precious metals tumbling, as markets reassessed the timeline for potential interest rate cuts.
U.S. equities found firmer ground Tuesday, buoyed by a robust factory activity report. The rally unfolded as investors grow increasingly discerning about AI-related capital expenditures, creating clear winners and losers.
The Labor Department has postponed the release of January's highly anticipated employment report, citing the ongoing partial government shutdown. This marks the second major delay in recent months for a key economic indicator that markets and policymakers rely on.
H.C. Wainwright maintains a Buy rating on Lexeo Therapeutics but slashes its price target, citing persistent market doubts over the company's PKP2 cardiomyopathy program despite encouraging early clinical results.
As Bitcoin and Ethereum lead a broad crypto sell-off, three altcoins buck the trend with notable gains. Analysts point to upcoming U.S. economic events as the next major catalyst for market direction.
The staggering cost of building AI infrastructure is pushing tech giants and startups alike into every corner of the debt market, from blue-chip bonds to private credit, reshaping investment portfolios and introducing new risks.
Despite a 5% share price gain over the last quarter, a deep dive into Fevara plc's (LON:FVA) fundamentals reveals concerning trends. With a declining net income and a high dividend payout strategy stifling reinvestment, analysts question the sustainability of its current valuation.
New long-term results from the pivotal EMBARK trial indicate ELEVIDYS, Sarepta's gene therapy, continues to alter the disease trajectory for boys with Duchenne muscular dystrophy, with no new safety concerns emerging over three years.
A week of significant stock swings saw Lockheed Martin and Texas Instruments surge on strong outlooks, while Humana plunged on regulatory headwinds. Here’s what drove the action and what analysts are saying.
Guggenheim Securities has initiated coverage of clinical-stage biopharma AtaiBeckley with a Buy rating and an $11 price target, highlighting its leadership in next-generation psychiatric treatments following its merger with Beckley Psytech.
From a $10 direct listing to a $150 S&P 500 constituent, Palantir's journey has been fueled by the AI boom. As government and commercial demand surge, analysts project staggering growth. But with sky-high valuations, the path forward requires navigating lofty expectations.
